Format

Send to

Choose Destination
Blood Rev. 2014 Nov;28(6):263-8. doi: 10.1016/j.blre.2014.08.003. Epub 2014 Sep 16.

Biosimilars: a cure to the U.S. health care cost conundrum?

Author information

1
Deparment of Medicine, Duke University Medical Center, USA; Duke Clinical Research Institute, Durham, NC, USA.
2
Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, USA; Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA. Electronic address: glyman@fhcrc.org.

Abstract

As the cost of healthcare continues to rise and patents on biologics near expiration, biosimilars are gaining visibility as a mechanism for cost reduction. Yet, the introduction of biosimilars into the U.S. market will be complex, due to the related complexity of production, research requirements, and regulatory uncertainty. The purpose of this paper is to frame the relevant issues in order to provide context for stakeholders. It is particularly crucial that clinicians understand the scientific, regulatory, legislative and economic considerations involved in order to ensure that the path to approval is consistent with their needs and that appropriate utilization occurs, once approved.

KEYWORDS:

Biosimilar; Follow-on biologic; Health care cost; Specialty pharmaceuticals

PMID:
25260225
DOI:
10.1016/j.blre.2014.08.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center